None provided


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH, Ludwig JA, Keedy V, Rietschel P, Kraft AS, Adkins D, Van Tine BA, Brockstein B, Yim V, Bitas C, Abdullah A, Antonescu CR, Condy M, Dickson MA, Vasudeva SD, Ho AL, Doyle LA, Chen HX, Maki RG (2013) Lancet Oncol 14(4): 371-82
    › Primary publication · 23477833 (PubMed) · PMC3766955 (PubMed Central)
  2. Signal transduction pathway analysis in desmoid-type fibromatosis: transforming growth factor-β, COX2 and sex steroid receptors. Mignemi NA, Itani DM, Fasig JH, Keedy VL, Hande KR, Whited BW, Homlar KC, Correa H, Coffin CM, Black JO, Yi Y, Halpern JL, Holt GE, Schwartz HS, Schoenecker JG, Cates JM (2012) Cancer Sci 103(12): 2173-80
    › Primary publication · 23035734 (PubMed) · PMC4278584 (PubMed Central)
  3. Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. Infante JR, Keedy VL, Jones SF, Zamboni WC, Chan E, Bendell JC, Lee W, Wu H, Ikeda S, Kodaira H, Rothenberg ML, Burris HA (2012) Cancer Chemother Pharmacol 70(5): 699-705
    › Primary publication · 22941375 (PubMed)
  4. Nuclear p63 expression in osteoblastic tumors. Kallen ME, Sanders ME, Gonzalez AL, Black JO, Keedy VL, Hande KR, Homlar KC, Halpern JL, Holt GE, Schwartz HS, Coffin CM, Cates JM (2012) Tumour Biol 33(5): 1639-44
    › Primary publication · 22623071 (PubMed)
  5. Identifying barriers associated with enrollment of patients with lung cancer into clinical trials. Horn L, Keedy VL, Campbell N, Garcia G, Hayes A, Spencer B, Carbone DP, Sandler A, Johnson DH (2013) Clin Lung Cancer 14(1): 14-8
    › Primary publication · 22591607 (PubMed)
  6. Signal transduction pathway analysis in fibromatosis: receptor and nonreceptor tyrosine kinases. Cates JM, Black JO, Itani DM, Fasig JH, Keedy VL, Hande KR, Whited BW, Homlar KC, Halpern JL, Holt GE, Schwartz HS, Coffin CM (2012) Hum Pathol 43(10): 1711-8
    › Primary publication · 22520949 (PubMed) · PMC4278590 (PubMed Central)
  7. Morphologic and immunophenotypic analysis of desmoid-type fibromatosis after radiation therapy. Cates JM, Black J, Wolfe CC, Shinohara ET, Holt GE, Keedy VL, Hande KR, Homlar KC, Halpern JL, Schwartz HS, Troutman A, Coffin CM (2012) Hum Pathol 43(9): 1418-24
    › Primary publication · 22404950 (PubMed)
  8. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, Milton DT, Strawn JR, Wakelee HA, Giaccone G (2011) J Clin Oncol 29(15): 2121-7
    › Primary publication · 21482992 (PubMed)
  9. Synchronous bone marrow metastasis from primary splenic angiosarcoma. Datta J, Toro TZ, Keedy VL, Merchant NB (2010) Am Surg 76(9): E160-2
    › Primary publication · 21396272 (PubMed)
  10. Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma. Sommer J, Itani DM, Homlar KC, Keedy VL, Halpern JL, Holt GE, Schwartz HS, Coffin CM, Kelley MJ, Cates JM (2010) J Pathol 220(5): 608-17
    › Primary publication · 20140939 (PubMed)
  11. Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapy. Moretti L, Yu DS, Chen H, Carbone DP, Johnson DH, Keedy VL, Putnam JB, Sandler AB, Shyr Y, Lu B (2009) Oncologist 14(11): 1106-15
    › Primary publication · 19897534 (PubMed) · PMC3045762 (PubMed Central)
  12. Cyclooxygenase 2 expression in soft tissue leiomyosarcoma. Herceg ME, Tsiatis AC, Halpern JL, Holt GE, Schwartz HS, Keedy VL, Cates JM (2009) Anticancer Res 29(8): 2913-7
    › Primary publication · 19661295 (PubMed)
  13. Prognostic significance of c-Myc expression in soft tissue leiomyosarcoma. Tsiatis AC, Herceg ME, Keedy VL, Halpern JL, Holt GE, Schwartz HS, Cates JM (2009) Mod Pathol 22(11): 1432-8
    › Primary publication · 19633646 (PubMed)
  14. Phase I study of adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioloalveolar cell lung carcinoma: ECOG 6597. Keedy V, Wang W, Schiller J, Chada S, Slovis B, Coffee K, Worrell J, Thet LA, Johnson DH, Carbone DP (2008) J Clin Oncol 26(25): 4166-71
    › Primary publication · 18757331 (PubMed) · PMC2654378 (PubMed Central)
  15. Does gefitinib shorten lung cancer survival? Chaos redux. Keedy VL, Arteaga CL, Johnson DH (2008) J Clin Oncol 26(15): 2428-30
    › Primary publication · 18378565 (PubMed)
  16. Inhibition of angiogenesis in the treatment of non-small cell lung cancer. Keedy VL, Sandler AB (2007) Cancer Sci 98(12): 1825-30
    › Primary publication · 17892508 (PubMed)
  17. Adjuvant and neoadjuvant approaches to treat surgically resectable pancreatic cancer. Keedy VL, Berlin J (2006) Curr Treat Options Oncol 7(5): 381-8
    › Primary publication · 16904055 (PubMed)